Literature DB >> 12529018

VEGF concentrations in tumour arteries and veins from patients with rectal cancer.

Kim Werther1, Steffen Bülow, Peter Hesselfeldt, Nils Frode Kragh Jespersen, Mads Nordahl Svendsen, Hans Jørgen Nielsen.   

Abstract

This pilot study investigated the hypothesis that the tumour itself is the source of the elevated vascular endothelial growth factor (VEGF) concentrations which are often observed in peripheral blood from patients with rectal cancer. Twenty-four consecutive patients with primary rectal cancer were included. Blood samples were drawn preoperatively from peripheral veins (I) and intraoperatively from peripheral veins (II), tumour arteries (III), and tumour veins (IV). In the four compartments, VEGF concentrations were measured in serum, EDTA plasma, and supernatants from lysed whole blood. Additionally, automated complete white cell and platelet counts were performed. In serum and EDTA plasma, no significant differences in VEGF concentrations were observed (p = 0.1 and p = 0.5), respectively) between tumour arteries and tumour veins. However, in supernatants from lysed blood, VEGF concentrations were significantly (p = 0.03) lower in venous blood than in arterial blood. Unexpectedly, a 16% reduction (p < 0.0001) in the number of neutrophils was observed during transit of the arterial blood through the rectal tumours, while none of the other types of leukocytes or platelets was significantly reduced in numbers during the same passage. These findings indicate that the tumour itself is not the only source of elevated VEGF concentrations in peripheral blood from patients with rectal cancer. A consistent finding was that a large number of neutrophils disappeared from the blood during passage through the rectal tumour. However, the significance and fate of the migrating neutrophils cells are unknown and should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529018     DOI: 10.1034/j.1600-0463.2002.1100908.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  Isolation and proteomic analysis of platelets by SELDI-TOF MS.

Authors:  Sean R Downing; Giannoula L Klement
Journal:  Methods Mol Biol       Date:  2012

2.  The use of specific anti-growth factor antibodies to abrogate the oncological consequences of transfusion in head & neck squamous cell carcinoma: an in vitro study.

Authors:  Tahwinder Upile; Waseem Jerjes; Sandeep Singh; Mohammed Al-Khawalde; Zaid Hamdoon; Hani Radhi; Colin Hopper
Journal:  Head Neck Oncol       Date:  2012-05-16

3.  alpha1-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells, in vitro.

Authors:  Inga Zelvyte; Tim Stevens; Ulla Westin; Sabina Janciauskiene
Journal:  Cancer Cell Int       Date:  2004-11-21       Impact factor: 5.722

4.  Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.

Authors:  Richard E Kast
Journal:  Med Sci (Basel)       Date:  2021-02-16

5.  Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.

Authors:  C Kut; F Mac Gabhann; A S Popel
Journal:  Br J Cancer       Date:  2007-10-02       Impact factor: 7.640

6.  Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Authors:  R E Kast
Journal:  Springerplus       Date:  2015-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.